United States v. Kaybel, Inc.’s Empirical Analysis
430 F.2d 1346 · 1970
Citation profile
5 federal appellate ·
How this case has been cited
Cited by 8 later decisions — most recently July 2023
5 federal appellate ·
Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.
Relationships
Applies 21 U.S.C. § 351 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 360 (Federal Food, Drug, and Cosmetic Act)
Relies on United States v. Various Articles of Drugs Consisting of Unknown Quantities of Prescription Drugs
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 8 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“Before placing [the Enovid 5mg.] on the market, [the original manufacturer] filed a new drug application with the Food and Drug Administration as required by the Food, Drug, and Cosmetic Act. 21 U.S.C. § 355 . The application was approved and became effective on March 9, 1961. While this approval was in effect, [the defendants] repackaged Eno-vid 5 mg. tablets from, the manufacturer’s original 500-unit bottles into its own 100-unit bottles, and sold the repackaged drug in interstate commerce.”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.